Abstract:We like to comment on the recently published article entitled “Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations” in the Journal of Thoracic Oncology. Deng et al.1Deng C. Zheng Q. Zhang Y. et al.Validation of the novel International Association for the Study of Lung Cancer grading system for invasive pulmonary adenocarcinoma and association with common driver mutations.J Thorac Oncol. 2021; 16: 1684-1693Google Scholar performed an interesting study regarding the prognostic significance of the novel grading system proposed by the International Association for the Study of Lung Cancer (IASLC) pathology committee and its correlations with common driver mutations and adjuvant chemotherapy. They found that the novel IASLC grading system was an efficient discriminator for patient prognosis. Nevertheless, we have some concerns. First, as illustrated in Supplementary Table 1, the authors presented the proportion of pathologic grades of lung adenocarcinoma according to the novel grading and previous predominant-based groups. There were 106 patients who were diagnosed with having well-differentiated adenocarcinoma according to predominant-based system, and 34 cases remained having grade 1 disease after reclassification, indicating 67.9% of the patients had high-grade patterns. Although patients with stages II to III were included in this study, this proportion was fairly higher compared with another two validation studies of the novel grading system. In the report of Kagimoto et al.,2Kagimoto A. Tsutani Y. Kambara T. et al.Utility of newly proposed grading system from International Association for the Study of Lung Cancer for invasive lung adenocarcinoma.JTO Clin Res Rep. 2020; 2: 100126Google Scholar there were 0.8% of patients upgrading from 1 to 3 after reclassification. Rokutan-Kurata et al.3Rokutan-Kurata M. Yoshizawa A. Ueno K. et al.Validation study of the International Association for the Study of Lung Cancer histologic grading system of invasive lung adenocarcinoma.J Thorac Oncol. 2021; 16: 1753-1758Google Scholar proposed that no patient with lepidic predominant patterns experienced upgrading after diagnosed with the novel grading system. Meanwhile, we consecutively reviewed 936 patients with invasive lung adenocarcinoma from January 2015 to December 2015 in three institutions, including Shanghai Pulmonary Hospital, the Second Affiliated Hospital of Soochow University, and Ningbo No. 2 Hospital. In our cohorts, 119 patients were previously diagnosed with having lepidic predominant adenocarcinoma and all of them were reclassified into grade 1 with the novel grading system, which was similar with the results of the aforementioned two studies. Thus, the high proportion of patients undergoing upgrading have probably affected the predictive performance of the IASLC grading system and previous predominant pattern-based system. Second, with regard to the prognostic impact of adjuvant chemotherapy in high-grade lung adenocarcinoma, the authors did not mention the predictive value of EGFR mutation status in multivariable survival analysis, neither with other mutations such as KRAS and ALK. It must be noted that the effectiveness of adjuvant chemotherapy would be affected by the status of driver mutations.4Shepherd F.A. Lacas B. Le Teuff G. et al.Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.J Clin Oncol. 2017; 35: 2018-2027Google Scholar,5Woodard G.A. Kratz J.R. Haro G. et al.Molecular risk stratification is independent of EGFR mutation status in identifying early-stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy.Clin Lung Cancer. 2021; 22: 587-595Google Scholar The evidence of the impact of adjuvant chemotherapy would be solid when the predictive value of common driver mutations was detailed. To sum up, the aforementioned points should be tackled before interpreting the results in clinical practice. Shenghui Li: Investigation, Methodology, Writing—original draft. Jiajun Deng: Validation, Writing—review and editing, Data curation. Yunlang She: Supervision, Visualization. Likun Hou: Resources, Supervision. Chang Chen: Conceptualization, Validation, Project administration. Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver MutationsJournal of Thoracic OncologyVol. 16Issue 10PreviewWe aimed to validate the use of the novel grading system proposed by the International Association for the Study of Lung Cancer pathology committee for prognosis stratification of invasive pulmonary adenocarcinomas (ADCs) in Chinese patients. Correlations between the grading system, common driver mutations, and adjuvant chemotherapy (ACT) were also investigated. Full-Text PDF Open ArchiveThe Grading System of Lung Adenocarcinoma: Ever-Evolving ConceptsJournal of Thoracic OncologyVol. 17Issue 3PreviewWe are thankful to Li et al. for their interest and commentary on our study validating the novel International Association for the Study of Lung Cancer grading system for invasive pulmonary adenocarcinoma (ADC).1 Their main concern centered on the relatively high proportion of patients upgrading to grade 3 on the basis of the novel grading system2 in our study. The architectural grading system only refers to the predominant histologic pattern, but most ADCs exhibit heterogeneous compositions. Moreover, the International Association for the Study of Lung Cancer grading system further classifies complex glandular patterns as high-grade patterns. Full-Text PDF Open Archive

Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association with Common Driver Mutations.

The IASLC Grading System for Invasive Pulmonary Adenocarcinoma: a Potential Prognosticator for Patients Receiving Neoadjuvant Therapy

Clinical Thoughts on the Predictive Value of the Newly Proposed Grading System of Invasive Pulmonary Adenocarcinoma

Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system

Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study

A Novel Radiopathological Grading System to Tailor Recurrence Risk for Pathologic Stage IA Lung Adenocarcinoma.

Validation of the Novel International Association for the Study of Lung Cancer Grading System and Prognostic Value of Filigree Micropapillary and Discohesive Growth Pattern in Invasive Pulmonary Adenocarcinoma.

[Prognostic Significance of a Newly Proposed Grading and Scoring System in Stage I Pulmonary Adenocarcinoma].

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

The IASLC Proposed Grading System Accurately Predicts Prognosis and Mediastinal Nodal Metastasis in Patients With Clinical Stage I Lung Adenocarcinoma

PET/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer

Application of the Novel Grading System of Invasive Pulmonary Adenocarcinoma in a Real Diagnostic Scenario: A Brief Report of 9353 Cases

A Prospective Comparison Study on EGFR Mutations by Direct Sequencing and ARMS in Completely Resected Chinese Non-Small Cell Lung Cancer with Adenocarcinoma Histology (ICAN).

A CT-Based Radiomics Nomogram Combined with Clinic-Radiological Characteristics for Preoperative Prediction of the Novel IASLC Grading of Invasive Pulmonary Adenocarcinoma.

Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma

College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Prognostic impact of the newly revised IASLC proposed grading system for invasive lung adenocarcinoma: a systematic review and meta-analysis

Frozen Sections Accurately Predict the IASLC Proposed Grading System and Prognosis in Patients with Invasive Lung Adenocarcinomas

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

P2.01-083 Prognostic Factors of Overall Survival in 150 Resected Lung Adenocarcinoma Patients: Topic: Marker for Prognosis